Sample size dosage strength pro­por­tion­ality study [Power / Sample Size]

posted by Laura R  – Israel, 2021-02-01 10:19 (672 d 11:51 ago) – Posting: # 22197
Views: 1,520

Dear Forum,
I was interesting to hear thoughts about the need to power a DP study for a 505b2:
BE between T and R will be demonstrated at one dose level. The PK of the drug is linear over the entire range however because of non-proportionality composition between T strengths we will run also a DP trial (for T only).
Power model at alpha = 0.05 will be used, so the 90% CI of the slope will be compared to the [0.80, 1.25] bounds.

Couldn't find any reference/guidance on the need to base sample size to achieve 80% or 90% power (in our case this will result in a very large study), and from review of precedents this sort of trials are many times non-powered and only descriptive.

Any comment is appreciated.

Best,

Complete thread:

UA Flag
Activity
 Admin contact
22,428 posts in 4,694 threads, 1,598 registered users;
17 visitors (0 registered, 17 guests [including 5 identified bots]).
Forum time: 22:10 CET (Europe/Vienna)

Statistics is the art of never having to say you’re wrong.
Variance is what any two statisticians are at.    C.J. Bradfield

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5